LEADER 05154oam 22012974 450 001 9910967325503321 005 20250426110455.0 010 $a9786613825070 010 $a9781462317509 010 $a1462317502 010 $a9781452790497 010 $a1452790493 010 $a9781283512626 010 $a1283512629 010 $a9781451909487 010 $a1451909489 035 $a(CKB)3360000000443499 035 $a(EBL)3014440 035 $a(SSID)ssj0000943026 035 $a(PQKBManifestationID)11967157 035 $a(PQKBTitleCode)TC0000943026 035 $a(PQKBWorkID)10974967 035 $a(PQKB)10802650 035 $a(OCoLC)694141092 035 $a(MiAaPQ)EBC3014440 035 $a(IMF)WPIEE2006235 035 $a(IMF)WPIEA2006235 035 $aWPIEA2006235 035 $a(EXLCZ)993360000000443499 100 $a20020129d2006 uf 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPublic Debt and Productivity : $eThe Difficult Quest for Growth in Jamaica /$fRodolphe Blavy 205 $a1st ed. 210 1$aWashington, D.C. :$cInternational Monetary Fund,$d2006. 215 $a1 online resource (27 p.) 225 1 $aIMF Working Papers 300 $a"October 2006." 311 08$a9781451864953 311 08$a1451864957 320 $aIncludes bibliographical references. 327 $a""Contents""; ""I. INTRODUCTION""; ""II. THE PARADOX: LOW GROWTH AND HIGH INVESTMENT ""; ""III. THE MISMEASUREMENT STORY""; ""IV. LOW PRODUCTIVITY: DOES THE LEVEL OF DEBT MATTER?""; ""V. HIGH DEBT AND DECLINING PRODUCTIVITY: THE CASE OF JAMAICA""; ""VI. TAKING STOCK: SUMMARY AND CONCLUSIONS""; ""REFERENCES"" 330 3 $aThe paper analyzes Jamaica's experience of low growth despite consistently high investment. Cross-country analysis provides evidence of a significant and negative relationship between total public debt and productivity growth. Looking at the specific channels through which high debt affects productivity growth and the allocation of resources in Jamaica, the study finds that high public debt has been associated with macroeconomic uncertainty and an output structure that relied excessively on a few maturing sectors with limited scope for productivity growth. Furthermore, public investment has been crowded out by debt service, further adversely affecting productivity growth. 410 0$aIMF Working Papers; Working Paper ;$vNo. 2006/235 517 3 $aDifficult quest for growth in Jamaica 606 $aDebts, Public$zJamaica 606 $aIndustrial productivity$zJamaica 606 $aPublic investments$zJamaica 606 $aDebt Management$2imf 606 $aDebt$2imf 606 $aDebts, Public$2imf 606 $aEconomics of specific sectors$2imf 606 $aEconomics$2imf 606 $aIndustrial productivity$2imf 606 $aInformal Economy$2imf 606 $aInformal economy$2imf 606 $aInformal sector$2imf 606 $aMacroeconomics$2imf 606 $aMacroeconomics: Production$2imf 606 $aNational Government Expenditures and Related Policies: Infrastructures$2imf 606 $aOther Public Investment and Capital Stock$2imf 606 $aProduction and Operations Management$2imf 606 $aProductivity$2imf 606 $aPublic debt$2imf 606 $aPublic finance & taxation$2imf 606 $aPublic Finance$2imf 606 $aPublic investment and public-private partnerships (PPP)$2imf 606 $aPublic investment spending$2imf 606 $aPublic investments$2imf 606 $aPublic-private sector cooperation$2imf 606 $aSovereign Debt$2imf 606 $aUnderground Econom$2imf 607 $aJamaica$xEconomic conditions 607 $aJamaica$2imf 615 0$aDebts, Public 615 0$aIndustrial productivity 615 0$aPublic investments 615 7$aDebt Management 615 7$aDebt 615 7$aDebts, Public 615 7$aEconomics of specific sectors 615 7$aEconomics 615 7$aIndustrial productivity 615 7$aInformal Economy 615 7$aInformal economy 615 7$aInformal sector 615 7$aMacroeconomics 615 7$aMacroeconomics: Production 615 7$aNational Government Expenditures and Related Policies: Infrastructures 615 7$aOther Public Investment and Capital Stock 615 7$aProduction and Operations Management 615 7$aProductivity 615 7$aPublic debt 615 7$aPublic finance & taxation 615 7$aPublic Finance 615 7$aPublic investment and public-private partnerships (PPP) 615 7$aPublic investment spending 615 7$aPublic investments 615 7$aPublic-private sector cooperation 615 7$aSovereign Debt 615 7$aUnderground Econom 700 $aBlavy$b Rodolphe$01815679 712 02$aInternational Monetary Fund.$bWestern Hemisphere Dept. 801 0$bDcWaIMF 906 $aBOOK 912 $a9910967325503321 996 $aPublic Debt and Productivity$94372817 997 $aUNINA LEADER 04652nam 2200613 a 450 001 9911019271403321 005 20230721004921.0 010 $a1-282-68493-0 010 $a9786612684937 010 $a1-4443-0016-4 010 $a1-4443-0017-2 035 $a(CKB)1000000000715953 035 $a(EBL)416408 035 $a(SSID)ssj0000151269 035 $a(PQKBManifestationID)11164263 035 $a(PQKBTitleCode)TC0000151269 035 $a(PQKBWorkID)10318086 035 $a(PQKB)11723878 035 $a(MiAaPQ)EBC416408 035 $a(MiAaPQ)EBC214179 035 $a(OCoLC)352829455 035 $a(EXLCZ)991000000000715953 100 $a20071211d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aEvidence-based dermatology /$fedited by Hywel Williams ; associate editors, Michael Bigby ... [et al.] 205 $a2nd ed. 210 $aMalden, Mass. ;$aOxford $cBlackwell Pub./BMJ Books$d2008 215 $a1 online resource (739 p.) 225 1 $aEvidence-Based Medicine 300 $aDescription based upon print version of record. 311 $a1-4051-4518-8 320 $aIncludes bibliographical references and index. 327 $aContributors; Foreword; Preface; I The concept of evidencebased; 1 The field and its boundaries; 2 The rationale for evidence-based dermatology; 3 The role of the consumer and the public in evidence-based dermatology; 4 The Cochrane Skin Group; II The critical appraisal; 5 Formulating well-built clinical questions; 6 Finding the best evidence; 7 The hierarchy of evidence; 8 Appraising systematic reviews and; 9 How to critically appraise a randomized controlled trial; 10 How to assess the evidence concerning the safety of medical interventions; 11 What makes a good case series? 327 $a12 What makes a good prevalence survey?13 Critical appraisal of; 14 Applying the evidence back; IIIa Common inflammatory skin diseases; 15 Acne vulgaris; 16 Papulopustular rosacea; 17 Perioral dermatitis; 18 Hand eczema; 19 Atopic eczema; 20 Seborrheic dermatitis; 21 Psoriasis; 22 Lichen planus; 23 Acute urticaria; 24 Chronic urticaria; IIIb Skin cancer, moles, and; 25 Primary prevention of skin cancer; 26 Do sunscreens reduce the incidence of; 27 Cutaneous melanoma; 28 Squamous cell carcinoma; 29 Basal cell carcinoma; 30 Primary cutaneous T-cell lymphoma 327 $a31 Actinic keratoses and Bowen's disease32 Kaposi's sarcoma; 33 Photoaging; 34 Melanocytic nevi; IIIc Infective skin diseases; 35 Local treatments for cutaneous warts; 36 Impetigo; 37 Athlete's foot; 38 Onychomycosis; 39 Tinea capitis; 40 Deep fungal infections; 41 Streptococcal cellulitis/erysipelas; 42 Exanthematic reactions; 43 Herpes simplex; 44 Leprosy; 45 Cutaneous leishmaniasis; IIId Infestations; 46 Scabies; 47 Head lice; 48 Insect bites and stings; IIIe Disorders of pigmentation; 49 Vitiligo; 50 Melasma; IIIf Hair problems; 51 Male and female androgenetic alopecia; 52 Alopecia areata 327 $a53 Evidence-based treatment of hirsutismIIIg Leg ulceration; 54 Venous ulcers; IIIh Other important skin; 55 Cutaneous lupus erythematosus; 56 Dermatomyositis; 57 Acquired subepidermal bullous diseases; 58 Pemphigus; 59 Cutaneous sarcoidosis; 60 Erythema multiforme; 61 Stevens-Johnson syndrome and toxic epidermal necrolysis; 62 Focal hyperhidrosis; 63 Polymorphic light eruption (PLE); 64 Infantile hemangiomas and port-wine stains; 65 Psychocutaneous disease; 66 Pruritus; 67 Other skin diseases for which trials exist; IV The future of evidencebased; 68 Where do we go from here?; Index 330 $aEvidence-based Dermatology, Second Edition is a unique book in the field of clinical dermatology. Written and edited by some of the world's leading experts in evidence-based dermatology, it takes a highly evidence-based approach to the treatment of all major and many of the less common skin conditions. The toolbox at the beginning of the book explaining how to critically appraise different studies, along with the comprehensive reviewing and appraisal of evidence in the clinical chapters makes this book distinctive in its field as do the treatment recommendations which are 410 0$aEvidence-Based Medicine 606 $aEvidence-based dermatology 615 0$aEvidence-based dermatology. 676 $a616.5 676 $a616.973 701 $aWilliams$b Hywel C$0955854 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911019271403321 996 $aEvidence-based dermatology$92163530 997 $aUNINA